Advertisement

Topics

Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma

16:08 EDT 14 Jun 2018 | OncLive

Ian Flinn, MD, PhD, discusses the activity and tolerability of 5F9 with rituximab in relapsed/refractory non-Hodgkin lymphoma, as well as intriguing findings with ibrutinib/venetoclax in frontline chronic lymphocytic leukemia.

Original Article: Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...